# CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients

Study · id `cardio:ct-nct05726526` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05726526](<https://clinicaltrials.gov/study/NCT05726526>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05726526

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 340 participants.

## Technical summary

Registry record NCT05726526. Randomized; single masking; primary purpose supportive care. Start 2022-06-30 (actual); primary completion 2027-03-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose supportive care
- Phase: Not applicable
- Enrolled: 340 participants (planned count; ClinicalTrials.gov record NCT05726526, source copy `cardio:ctgov-nct05726526-2026-09-10`, retrieved 2026-10-26)
- Started: 2022-06-30 (actual) (ClinicalTrials.gov record NCT05726526, source copy `cardio:ctgov-nct05726526-2026-09-10`, retrieved 2026-10-26)
- Primary completion: 2027-03-30 (anticipated) (ClinicalTrials.gov record NCT05726526, source copy `cardio:ctgov-nct05726526-2026-09-10`, retrieved 2026-10-26)
- Completion: 2028-03-30 (anticipated) (ClinicalTrials.gov record NCT05726526, source copy `cardio:ctgov-nct05726526-2026-09-10`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT05726526, source copy `cardio:ctgov-nct05726526-2026-09-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05726526-2026-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
- Acronym: VIEWER
- Condition: Chronic Kidney Disease Stage 5
- Condition: End Stage Renal Disease
- Intervention (Device): VIEWER virtual care platform
- Lead sponsor: University of Manitoba
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: cc1087ae99f30b2f401e38c51088af635db1f8ccd985ab0c7322b54cd4a5b8ac
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
